[1] Jasty M, Bragdon C, Burke D. In vivo skeletal response to porous surfaced implants subjected to small induced motion[J]. J Bone Joint Surg Am, 1997, 79(5): 707-714. [2] Klawitter JJ, Hulbert SF. Application of porous ceramics for the attachment of load bearing internal orthopaedic application[J]. J Biomed Mater Res, 1971, 2(1): 161-166. [3] Astrand J, Aspenberg P. Alendronate did not inhibit instability-induced bone resorption:A study in rats[J]. Acta Orthop Scand, 1999, 70(1): 67-70. [4] Astrand J, Aspenberg P. Reduction of instability-induced bone resorption using bisphosphonates:High doses are needed in rats[J]. Acta Orthop Scand, 2002, 73(1): 24-30. [5] Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis[J]. N Engl J Med, 2003, 349(13): 1207-1215. [6] Cao Y, Mori S, Mashiba T, et al. Raloxifene, estrogen and alendronate affect the processes of fracture repair differently in ovariectomized rats[J]. J Bone Miner Res, 2002, 17(12): 2237-2246. [7] Halasy-Nagy JM, Rodan GA, Reszka AA. Inhibition of bone resorption by alendronatr and risedronatr does not require osteoclast apoptosis[J]. Bone, 2001, 29(6): 553-559. [8] Giavaresi G, Fini M, Gnudi S, et al. Comparison of calcitonin, alendroate and fluorophosphate effects on wvariectomized rat bone[J]. Biomed Pharmacother, 2001, 55(7): 397-403. [9] Sato M, Grasser W, Endo N, et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure[J]. J Clin Invest, 1991, 88(6): 2095-2105. [10] Tayior M, Tanner KE. Fatigue failure of ancellous bone: apossible cause of implant migration and loosening[J]. J Bone Joint Surg Br, 1997, 79(2): 181-182. [11] Camacho NP, Brayton CF, Buckmeyer J, et al. Evaluation of alendronate for treatment in an animal model of osteogenesis imperfecta[J]. J Bone Miner Res, 1997, 12(Suppl):S389. |